Base Year
Historical Year
Forecast Year
The sarcoidosis market size is expected to grow at a CAGR of 3.8% during the forecast period of 2024-2032, driven by the extensive research activities aimed at finding effective therapeutic solutions and the growing demand for personalized medicines across the 8 major markets.
Sarcoidosis is an inflammatory disease characterized by the formation of tiny granulomas or lumps. It predominantly affects the lungs or lymph nodes, resulting in inflammation and possible organ damage. Depending on the region, the annual incidence of the disease ranges from 1 to 15 per 100,000 individuals, with higher rates found in North America (5-10/100,000) and the highest in Northern Europe (11-15/100,000). The rising burden of sarcoidosis is projected to drive the sarcoidosis market growth in the forecast period.
Factors such as increased funding from various sectors and extensive research initiatives are positively impacting the market landscape. In December 2023, the Foundation for Sarcoidosis Research (FSR) awarded a grant of USD 100,000 to support two United States-based research projects involved in understanding the disease and diagnosis of cardiac sarcoidosis, with each project receiving USD 50,000. The funding is expected to encourage research in diagnosis techniques, prognosis, and treatment alternatives for cardiac sarcoidosis. Till now, FSR has awarded USD 6.5 million for sarcoidosis research via its grant program. Such fundings provide essential support to accommodate the growing sarcoidosis market demand and contribute to the market growth significantly.
The market is also driven by the surge in drug approvals by regulatory health agencies such as the United States Food and Drug Administration (FDA) to meet the clinical needs of patients suffering from sarcoidosis. Moreover, the rising patient awareness and the advancement in the healthcare sector is poised to fuel market growth.
| Key Trend | Impact |
| Advancements in Diagnostic Techniques | Improved diagnostic techniques, including advanced imaging technologies and molecular diagnostic tools, are increasing the accuracy and efficiency of sarcoidosis diagnosis. |
| Emergence of Targeted Therapies | The development of targeted therapies aimed at specific pathways and mechanisms involved in sarcoidosis is resulting in more effective and less toxic treatment options compared to traditional therapies. |
| Increased Focus on Personalized Medicine | Personalized medicine approaches are driving demand in the sarcoidosis market, with research aimed at identifying genetic markers and other biomarkers that can predict disease progression and treatment response. |
| Increased Clinical Trials | There is a notable increase in the number of clinical trials for sarcoidosis, focusing on new therapeutic agents. This expansion is driven by the unmet need for more effective and tolerable treatments. |
Market Breakup by Diagnostic Method
The market segmentation by diagnostic methods includes imaging techniques, biopsy, and blood tests. Imaging techniques comprise chest X-rays, CT scans, and MRI scans to visualize affected areas. Biopsy procedures such as bronchoscopy, skin biopsy, and lymph node biopsy provide tissue samples for examination. Blood tests measure angiotensin-converting enzyme (ACE) levels, serum calcium levels, and liver function for a comprehensive assessment.
Market Breakup by Treatment Type
By treatment type, the market is divided into various options: corticosteroids, including oral and inhaled forms, to manage inflammation, immunosuppressive agents like methotrexate, azathioprine, and mycophenolate mofetil, biologics such as tumor necrosis factor (TNF) inhibitors and interleukin inhibitors and anti-malarial drugs like hydroxychloroquine offer additional therapeutic interventions.
Market Breakup by Route of Administration
The sarcoidosis market share is segmented by route of administration into oral, and parenteral, among others. Oral medications are taken by mouth, while parenteral options involve injection or infusion.
Market Breakup by End User
End users of the market are hospitals, specialty clinics, homecare, and others. This market segment represents treatment and care settings for the sarcoidosis patients.
Market Breakup by Distribution Channel
Based on distribution channels, the sarcoidosis market segmentation is divided into hospital pharmacy, retail pharmacy, online pharmacy, and others.
Market Breakup by Region
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and China. North America leads the market share supported by the rising investments from the key market players to address the unmet needs of sarcoidosis patients. In addition, the advanced healthcare infrastructure and access to various treatment options are also driving the market demand.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Diagnostic Method |
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is anticipated to grow at a CAGR of 3.8% during the forecast period of 2024-2032, driven by the extensive research activities aimed at finding effective therapeutic solutions and the growing demand for personalized medicines across the 8 major markets.
The market demand is driven by the emergence of targeted therapies and advancement in diagnostic techniques.
One of the significant trends in the market is the increased funding to support sarcoidosis-related research. In December 2023, the Foundation for Sarcoidosis Research (FSR) awarded a grant of USD 100,000 to support two United States-based research projects involved in understanding the disease and diagnosis of cardiac sarcoidosis, with each project receiving USD 50,000.
Based on the treatment type, the market is segmented into corticosteroids, immunosuppressive agents, biologics, and anti-malarial drugs. Corticosteroids are further divided into oral and inhaled forms. Immunosuppressive agents include methotrexate, azathioprine, and mycophenolate mofetil, while biologics include tumor necrosis factor (TNF) inhibitors and interleukin inhibitors. Anti-malarial drugs like hydroxychloroquine are also used as a treatment type.
Diagnostic methods available in the market include imaging techniques, biopsy, and blood tests.
The sarcoidosis market share is segmented by route of administration into oral, and parenteral, among others.
Major end users of the market are hospitals, specialty clinics, homecare, and others.
Distribution channels in the market include hospital pharmacies, retail pharmacies, online pharmacies, and others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and China.
Key players involved in the market are Merck & Co., Inc., Fresenius Kabi USA, Zydus Pharmaceuticals, Inc., Sanofi-aventis U.S. LLC, Hoffmann-La Roche Ltd, Teva Pharmaceuticals USA, Inc., Sandoz International GmbH, Relief Therapeutics, Pfizer Inc., AbbVie Inc., Mallinckrodt, Amneal Pharmaceuticals LLC, Mylan N.V., and Hikma Pharmaceuticals PLC.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share